Biomedical Sciences Personal Statementfor Oxford & Imperial

The first time I understood why I wanted to study biomedical sciences was when the MHRA authorised the Pfizer-BioNTech Covid-19 vaccine for use in the UK on 2 December 2020. What held my attention was not only the speed of the rollout but the biology behind it: a strand of mRNA had to survive delivery, enter cells, be translated, and trigger protection without provoking the wrong kind of immune response. That sequence made treatment feel less like a finished product and more like a chain of molecular decisions. Reading about Katalin Karikó and Drew Weissman's work on nucleoside base modifications sharpened that interest. I had assumed the difficult part of a vaccine was identifying the right antigen, but their work showed that the behaviour of the RNA itself, including whether it would be recognised as dangerously foreign, was just as important. What attracts me to biomedical sciences is that it sits where molecular explanation meets human consequence. I am especially interested in immunology and molecular pathology because they show how cellular mechanisms can be translated into diagnostics and targeted treatments while still leaving real questions about variability, uncertainty and how illness is experienced by patients.

My qualifications have prepared me for biomedical sciences by teaching me to move between detail and consequence. In Biology and Chemistry, cell signalling, transcription and translation interested me because they showed how a small molecular change can alter a wider physiological outcome. Immunology was especially important to me because antigen presentation made immune recognition feel precise rather than abstract: the body responds to an edited display of peptide fragments, not simply to a pathogen in general. That pushed me to think more critically about why two interventions aimed at the same disease can behave differently once they meet living tissue. Practical work reinforced that habit of mind. In serial dilutions and colorimetric assays, small inconsistencies in pipetting, timing or sample handling altered results enough to make reliability feel like a scientific problem rather than just a classroom rule. My EPQ extended this further. I examined how far mRNA vaccine platforms could be adapted beyond Covid-19 and expected to end with a confident argument about their versatility. Instead, comparing review articles with primary papers made me more cautious, particularly around therapeutic uses such as cancer vaccines. I kept returning to delivery: encoding the right protein was not enough if stability, tissue targeting and immune activation were not also controlled. Rewriting sections after checking the original papers taught me to pay closer attention to conditions, sample limits and what a study had not yet shown.